Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
TNFR[1]
|
---|---|
ln Vitro |
Lenercept (TNFR-IgG) has an IC50 of 0.5 μg/mL and 1.5 μg/mL, respectively, and inhibits the cytolysis of TNF-α and TNF-β in actinomycin D (HY-17559)-treated mouse LM cells. [2].
|
ln Vivo |
Lenercept (Ro 45-2081) prevents rats from suffering lung damage from Sephadex [1]. Lenercept (TNFR-IgG; 0.8–20 μg/mouse; iv; once) given prior to or soon after endotoxin exposure prevents or considerably delays endotoxin-induced mortality in mice [2]
|
Animal Protocol |
Animal/Disease Models: Male SD (Sprague-Dawley) rats[1]
Doses: 1 and 3 mg/kg Route of Administration: intraperitoneal (ip)injection, 1 h before administration of Sephadex for the 24 h study or 1 h before and at 24 and 48 h after Sephadex for the 72 h study Experimental Results: Inhibited the neutrophilia at 24 h after Sephadex. At 72 h after Sephadex, Dramatically diminished the neutrophil influx into bronchialveolar lavage fluid (BALF) but had no inhibitory effect on eosinophil number. Animal/Disease Models: 6- to 8weeks old female balb/c (Bagg ALBino) mouse:, septic shock model[2] Doses: 0.8, 4 or 20 μg/mouse Route of Administration: IV, single dose Experimental Results: Injection 0.5 h prior to Salmonella abortus-derived endotoxin (LD100 dose) administration prevented lethality at a dose of 20 μg per mouse and provided partial protection at lower doses. Injection of 10 μg per mouse provided significant protection 0.5 h before, 0.5 h after, or 1 h after endotoxin injection but little protection 2 h after endotoxin injection. |
References |
[1]. Gater PR, et al. Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein. Am J Respir Cell Mol Biol. 1996 May;14(5):454-60.
[2]. Ashkenazi A, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10535-9. |
Molecular Formula |
C1993H3112N562O624S34
|
---|---|
CAS # |
156679-34-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.